Bare Lymphocyte Syndrome

Search Trials
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
Status:
Recruiting
Last Changed:
Aug 7, 2019
First Changed:
Apr 5, 2019
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo
A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
Status:
Withdrawn
Last Changed:
Mar 18, 2019
First Changed:
Nov 27, 2017
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo
Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION
Status:
Terminated
Last Changed:
Aug 7, 2013
First Changed:
Jun 28, 2011
Disease(s):
Cholestasis, Progressive Familial Intrahepatic 3
Intervention(s):
Yttrium microsphere injection
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Status:
Recruiting
Last Changed:
Apr 5, 2019
First Changed:
Oct 14, 2013
Disease(s):
Primary Immunodeficiency (PID)
Intervention(s):
HydroxyureaAlemtuzumabFludarabineMelphalanThiotepa
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Status:
Recruiting
Last Changed:
Jan 15, 2019
First Changed:
Jul 27, 2012
Disease(s):
SCID
Intervention(s):
Alemtuzumab 0.3 mgCyclophosphamideBusulfanStem Cell TransplantationFludarabine phosphate 40 mgMelphalanAlemtuzumab 0.2 mgBusulfanFludarabine phosphate 30 mgMESNA

Connect. Empower. Inspire.